Persons with schizophrenia frequently first come to clinical attention during an acute exacerbation of the illness. Jibson updates state-of-the-art pharmacologic treatment of acute schizophrenia, noting that the foundation for successful recovery is frequently laid by the quality of treatment decisions and planning in this acute phase.
In contrast to pharmacotherapy, the role of psychotherapeutic interventions in the treatment of schizophrenia is poorly recognized. Kuipers describes the evolving role of cognitive-behavioral therapy and family intervention in the treatment of schizophrenia and provides some practical recommendations about their application in clinical practice today.
Collectively, these articles underscore some of the major challenges and opportunities in our efforts to improve outcomes for individuals with schizophrenia. While existing treatments may not be completely satisfactory, they can substantially reduce disease burden and make a meaningful difference in the lives of patients. Even as we strive to develop more effective treatments for the future, we can improve our use of existing treatments to optimize individual outcomes and reduce the considerable morbidity and mortality associated with schizophrenia.
Related Links
Biological Markers and the Future of Early Diagnosis and Treatment in Schizophrenia
The Metabolic Syndrome and Schizophrenia: Clinical Research Update
Childhood-Onset Schizophrenia: Diagnostic and Treatment Challenges
Psychological Therapies for Schizophrenia: Family and Cognitive Interventions
Pharmacotherapy of Acute Schizophrenia
Dr Tandon is adjunct professor of psychiatry at the University of Florida in Gainesville and chief of psychiatry in the office of mental health at the State of Florida Department of Children and Families in Tallahassee. This article is not part of the purview of Dr Tandon's current employment by the State of Florida, which bears no responsibility for its contents. The author has disclosed that he has no current significant relationships with or financial interests in any commercial organizations pertaining to this activity.
Reference
1. Tandon R, Targum SD, Nasrallah HA, Ross R. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. J Psychiatr Pract. 2006;12:348-363
